Elena Barbieri
@elenabarbieri.bsky.social
Medical Oncologist at AOU Modena 🇮🇹 with special interest in breast cancer and oncogenetics. Addicted to football, running and travelling.
Reposted by Elena Barbieri
Impact of risk reducing surg for young women with BRCA (Lambertini). Zest (Turner) about ctDNA in high risk early stage disease, what have we learned!
of course many more... @oncoalert.bsky.social
of course many more... @oncoalert.bsky.social
Agree with the list, big data coming up! - a few more here and to follow: COMET, important trial evaluating watch and wait vs surgery for low risk DCIS (Hwang). PADMA: RW study of Pablo/letrozole vs chemo for metastatic disease (Loibl).
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 19, 2024 at 2:55 AM
Impact of risk reducing surg for young women with BRCA (Lambertini). Zest (Turner) about ctDNA in high risk early stage disease, what have we learned!
of course many more... @oncoalert.bsky.social
of course many more... @oncoalert.bsky.social
Reposted by Elena Barbieri
The third National Congress of the Italian Society for Familial and Hereditary Tumors #AIFET is going to start in the wonderful Camogli!
(Let’s start a new adventure with 🦋)
(Let’s start a new adventure with 🦋)
November 20, 2024 at 9:23 PM
The third National Congress of the Italian Society for Familial and Hereditary Tumors #AIFET is going to start in the wonderful Camogli!
(Let’s start a new adventure with 🦋)
(Let’s start a new adventure with 🦋)